Erik Ingelsson - 09 Apr 2026 Form 3 Insider Report for Wave Life Sciences Ltd. (WVE)

Reporting relationship: Chief Scientific Officer
Issuer ticker: WVE
Reported as of: 09 Apr 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 17 Apr 2026, 21:00:03 UTC
Source filing: View source filing
Reporting owner signature: /s/ Erik Ingelsson

Key filing fact

Erik Ingelsson filed Form 3 for Wave Life Sciences Ltd. (WVE) on 17 Apr 2026.

Key facts

This page summarizes Erik Ingelsson's Form 3 filing for Wave Life Sciences Ltd. (WVE).
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 17 Apr 2026, 21:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002129693 Primary reporting owner

Ingelsson Erik

Relationship: Chief Scientific Officer
Address: C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE
Signature: /s/ Erik Ingelsson
Signature date: 17 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WVE holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 87,864
Date: 09 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WVE holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 09 Apr 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 350,000
Exercise price: $5.85
Footnotes: F2

WVE holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 09 Apr 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 200,000
Exercise price: $11.74
Footnotes: F3

WVE holding Derivative

Share Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 09 Apr 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 273,750
Exercise price: $12.75
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Consists of (i) 17,489 ordinary shares, (ii) 24,750 RSUs that vest in three equal annual installments on February 8, 2027 through February 8, 2029; and (iii) 45,625 RSUs that vest in four equal annual installments of 25% beginning on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F2

The option vested as to 25% of the shares on May 8, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until May 8, 2028, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F3

The option vested as to 25% of the shares on February 8, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2029, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F4

The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.

SEC remarks

Exhibit 24.1 - Power of Attorney